Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases

3542 Background: Metastatic colorectal cancer has a 5-year survival < 5% but increases to 30% in patients (pts) who undergo complete resection. Neoadjuvant systemic (SYS) chemotherapy may increase the proportion of patients suitable for resection, but this is unlikely to occur after first line chemotherapy failure, given the 10 - 15% response rates of second line SYS Oxal (Rothenberg et al, J Clin Oncol 2003:21;2059, Tournigand et al, Proc Am Soc Clin Oncol 2001;20:abstr 494). HAI plus SYS Oxal may be more effective in this regard, especially in previously treated patients. Methods: Forty-four patients with liver only metastatic colorectal cancer were deemed unresectable by experienced hepatobiliary surgeons. They were treated on either of two phase I trials consisting of HAI (floxuridine and dexamethasone) plus either SYS Oxal with irinotecan (CPT-11) or SYS Oxal with fluorouracil and leucovorin. Responding pts proceeded to surgery if deemed resectable. Results: The overall response rate using HAI plus S...